SI1079843T1 - Uporaba inhibitorjev receptorja alfa1beta1-integrina in inhibitorjev TGF-beta1 pri zdravljenju ledvične bolezni - Google Patents

Uporaba inhibitorjev receptorja alfa1beta1-integrina in inhibitorjev TGF-beta1 pri zdravljenju ledvične bolezni

Info

Publication number
SI1079843T1
SI1079843T1 SI9930967T SI9930967T SI1079843T1 SI 1079843 T1 SI1079843 T1 SI 1079843T1 SI 9930967 T SI9930967 T SI 9930967T SI 9930967 T SI9930967 T SI 9930967T SI 1079843 T1 SI1079843 T1 SI 1079843T1
Authority
SI
Slovenia
Prior art keywords
alpha
inhibitors
integrin receptor
tgf
kidney disease
Prior art date
Application number
SI9930967T
Other languages
English (en)
Inventor
Dominic Cosgrove
Original Assignee
Bpys Town Nat Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bpys Town Nat Res Hospital filed Critical Bpys Town Nat Res Hospital
Publication of SI1079843T1 publication Critical patent/SI1079843T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/18Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • Y10S977/907Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI9930967T 1998-05-22 1999-05-19 Uporaba inhibitorjev receptorja alfa1beta1-integrina in inhibitorjev TGF-beta1 pri zdravljenju ledvične bolezni SI1079843T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
EP99923224A EP1079843B1 (en) 1998-05-22 1999-05-19 Use of alfa1beta1 integrin receptor inhibitors and tgf- beta1 inhibitors in the treatment of kidney disease
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
SI1079843T1 true SI1079843T1 (sl) 2007-10-31

Family

ID=56289911

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930967T SI1079843T1 (sl) 1998-05-22 1999-05-19 Uporaba inhibitorjev receptorja alfa1beta1-integrina in inhibitorjev TGF-beta1 pri zdravljenju ledvične bolezni

Country Status (21)

Country Link
EP (1) EP1079843B1 (sl)
JP (1) JP2002516287A (sl)
CN (1) CN1187084C (sl)
AT (1) ATE359804T1 (sl)
BR (1) BR9911067A (sl)
CA (1) CA2329757C (sl)
CZ (1) CZ296262B6 (sl)
DE (1) DE69935853T2 (sl)
DK (1) DK1079843T3 (sl)
EA (1) EA004145B1 (sl)
EE (1) EE04581B1 (sl)
ES (1) ES2285841T3 (sl)
HU (1) HUP0202048A3 (sl)
NO (1) NO20005883L (sl)
NZ (1) NZ508317A (sl)
PL (1) PL345946A1 (sl)
PT (1) PT1079843E (sl)
SG (1) SG117434A1 (sl)
SI (1) SI1079843T1 (sl)
TR (1) TR200003432T2 (sl)
WO (1) WO1999061040A2 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
PT1214091E (pt) * 1999-09-14 2006-09-29 Imperial College Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina
CA2400628A1 (en) * 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
US7358054B2 (en) 2001-04-13 2008-04-15 Biogen Idec Ma Inc. Antibodies to VLA-1
WO2004041846A2 (en) * 2002-11-01 2004-05-21 Boys Town National Research Hospital INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
EA030211B1 (ru) 2012-04-25 2018-07-31 Регьюлэс Терапьютикс Инк. Соединения на основе микрорнк и способы модулирования активности mir-21
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN104450726A (zh) * 2013-09-17 2015-03-25 深圳华大基因科技有限公司 Col4a5基因突变体及其应用
CN104212806B (zh) * 2014-07-21 2017-05-17 深圳华大基因股份有限公司 Alport综合征新的突变致病基因及其编码蛋白和应用
EP4225302A1 (en) * 2020-10-05 2023-08-16 Father Flanagan's Boys' Home doing Business as Boys Town National Research Hospital Combination therapy for alport renal disease
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ube株式会社 アルポート症候群を治療または予防するための医薬組成物
CN114698592B (zh) * 2022-04-29 2022-11-04 中国医学科学院北京协和医院 一种干燥综合征肾损害小鼠模型的构建方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition

Also Published As

Publication number Publication date
NO20005883D0 (no) 2000-11-21
CA2329757A1 (en) 1999-12-02
TR200003432T2 (tr) 2001-03-21
PT1079843E (pt) 2007-06-26
CN1310625A (zh) 2001-08-29
EE200000685A (et) 2002-04-15
EA004145B1 (ru) 2004-02-26
WO1999061040A2 (en) 1999-12-02
CA2329757C (en) 2013-11-19
DE69935853T2 (de) 2008-01-10
HUP0202048A3 (en) 2006-11-28
ATE359804T1 (de) 2007-05-15
BR9911067A (pt) 2001-02-06
EP1079843A2 (en) 2001-03-07
JP2002516287A (ja) 2002-06-04
DK1079843T3 (da) 2007-07-30
DE69935853D1 (de) 2007-05-31
PL345946A1 (en) 2002-01-14
CZ20004358A3 (cs) 2002-01-16
CN1187084C (zh) 2005-02-02
NZ508317A (en) 2004-01-30
EE04581B1 (et) 2006-02-15
HUP0202048A2 (en) 2002-10-28
SG117434A1 (en) 2005-12-29
NO20005883L (no) 2001-01-17
CZ296262B6 (cs) 2006-02-15
WO1999061040A3 (en) 2000-01-27
WO1999061040A9 (en) 2001-02-01
EP1079843B1 (en) 2007-04-18
ES2285841T3 (es) 2007-11-16
EA200001092A1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
SG117434A1 (en) Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
GB9818916D0 (en) Use
HUP0301577A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
NO992282L (no) Benzonaftyridiner som bronkialterapentika
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
NO994431L (no) Ny formulering
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
TR200200278T2 (tr) Kalsilitik bileşimler
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
BG105097A (en) Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
WO2002006280A3 (en) INHIBITORS OF FACTOR Xa
ZA966577B (en) Pharmaceutical composition.
GB9802542D0 (en) New use
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
FR2802101B1 (fr) Association de cymemazine et d'un neuroleptique atypique